Cargando…

CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton’s tyrosine kinase

Bruton's tyrosine kinase (BTK) regulates the B-cell receptor (BCR) signaling pathway, which, in turn, plays a critical role in B-cell chronic lymphocytic leukemia (B-CLL) pathogenesis. The BTK-specific inhibitor Ibrutinib blocks BCR signaling and is now approved as effective B-CLL therapy. Chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montresor, Alessio, Toffali, Lara, Rigo, Antonella, Ferrarini, Isacco, Vinante, Fabrizio, Laudanna, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205546/ https://www.ncbi.nlm.nih.gov/pubmed/30416684 http://dx.doi.org/10.18632/oncotarget.26212

Ejemplares similares

JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia
por: Montresor, Alessio, et al.
Publicado: (2015)

JAK tyrosine kinases promote hierarchical activation of Rho and Rap modules of integrin activation
por: Montresor, Alessio, et al.
Publicado: (2013)

Monocyte-to-macrophage switch reversibly impaired by Ibrutinib
por: Ferrarini, Isacco, et al.
Publicado: (2019)

Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol α-bisabolol, a dual proapoptotic and antiautophagic agent
por: Rigo, Antonella, et al.
Publicado: (2018)

Chemokines and the Signaling Modules Regulating Integrin Affinity
por: Montresor, Alessio, et al.
Publicado: (2012)

The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
por: Ferrarini, Isacco, et al.
Publicado: (2020)

A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level
por: Rigo, Antonella, et al.
Publicado: (2018)

West Nile Virus Encephalitis in Haematological Setting: Report of Two Cases and a Brief Review of the Literature
por: Ferrarini, Isacco, et al.
Publicado: (2019)

CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin
por: Rigo, Antonella, et al.
Publicado: (2012)

Node Interference and Robustness: Performing Virtual Knock-Out Experiments on Biological Networks: The Case of Leukocyte Integrin Activation Network
por: Scardoni, Giovanni, et al.
Publicado: (2014)

Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase
por: Cuesta-Domínguez, Álvaro, et al.
Publicado: (2012)

BID and the α-bisabolol-triggered cell death program: converging on mitochondria and lysosomes
por: Rigo, Antonella, et al.
Publicado: (2019)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

T cells JAK up integrin activity
por: Short, Ben
Publicado: (2013)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
por: Xia, Simo, et al.
Publicado: (2019)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
por: Qiu, Simei, et al.
Publicado: (2021)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2019)

Bruton's Tyrosine Kinase Links the B Cell Receptor to Nuclear Factor κb Activation
por: Bajpai, Urmila D., et al.
Publicado: (2000)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Enhanced Bruton’s tyrosine kinase activity in the kidney of patients with IgA nephropathy
por: Wei, Jie, et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Evidence for enhanced Bruton’s tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis
por: von Borstel, Anouk, et al.
Publicado: (2019)

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
por: Turetsky, Anna, et al.
Publicado: (2014)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
por: Cho, Hyewon, et al.
Publicado: (2020)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_urt10nssn43jmo0t363l31a22e